Form 4: Rhythm Pharmaceuticals CEO Sells Shares
Insider Transaction (Form 4)
David P Meeker, President and CEO and a Director of Rhythm Pharmaceuticals, Inc., sold 50,000 shares of common stock on September 14, 2026.
Summary
- Option exercise/conversion: acquired 50,000 Common Stock at $6.05 ($302,500) on September 14, 2026; holds 289,258 after (Direct).
- Open-market sale: disposed of 6,439 Common Stock at $101.75 ($655,145) on September 14, 2026; holds 282,819 after (Direct).
- Open-market sale: disposed of 30,746 Common Stock at $102.35 ($3,146,761) on September 14, 2026; holds 252,073 after (Direct).
- Open-market sale: disposed of 8,698 Common Stock at $103.43 ($899,634) on September 14, 2026; holds 243,375 after (Direct).
- Open-market sale: disposed of 1,817 Common Stock at $104.55 ($189,965) on September 14, 2026; holds 241,558 after (Direct).
- Open-market sale: disposed of 2,300 Common Stock at $105.19 ($241,937) on September 14, 2026; holds 239,258 after (Direct).
- Option exercise/conversion: disposed of 50,000 Employee Stock Option (Right to Buy) on September 14, 2026; holds 15,431 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,133,442 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
David P Meeker — Director, Officer (President and CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-14 | Option exercise/conversion | Common Stock | 50,000 | $6 | $302.5K | 289,258 |
| 2026-09-14 | Open-market sale | Common Stock | 6,439 | $102 | $655.1K | 282,819 |
| 2026-09-14 | Open-market sale | Common Stock | 30,746 | $102 | $3.1M | 252,073 |
| 2026-09-14 | Open-market sale | Common Stock | 8,698 | $103 | $899.6K | 243,375 |
| 2026-09-14 | Open-market sale | Common Stock | 1,817 | $105 | $190.0K | 241,558 |
| 2026-09-14 | Open-market sale | Common Stock | 2,300 | $105 | $241.9K | 239,258 |
| 2026-09-14 | Option exercise/conversion | Employee Stock Option (Right to Buy) | 50,000 | — | — | 15,431 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-14 | Option exercise/conversion (50,000 shares) |
| 2026-09-14 | Open-market sale (6,439 shares) |
| 2026-09-14 | Open-market sale (30,746 shares) |
| 2026-09-14 | Open-market sale (8,698 shares) |
| 2026-09-14 | Open-market sale (1,817 shares) |
| 2026-09-14 | Open-market sale (2,300 shares) |
| 2026-09-14 | Option exercise/conversion (50,000 shares) |
Keywords
insider transaction, Form 4, RYTM, RHYTHM PHARMACEUTICALS, INC., bearish, David P Meeker
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.